PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: A61K 41/00 — A1

(11) International Publication Number: **WO 00/01411**

(43) International Publication Date: 13 January 2000 (13.01.00)

(21) International Application Number: PCT/EP99/04545

(22) International Filing Date: 30 June 1999 (30.06.99)

(30) Priority Data:

98202257.6	6 July 1998 (06.07.98)	EP
98204330.9	18 December 1998 (18.12.98)	EP

(71) Applicant *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Patent Dept., Turnhoutseweg 30, B–2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: VAN GINCKEL, Robert, Franciscus [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). FLOREN, Wim, Joanna [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). END, David, William [US/US]; Janssen Research Foundation, Welsh and McKean Roads, Spring House, PA 19477–0776 (US). WOUTERS, Walter, Boudewijn, Leopold [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE).

(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept. – ext. 3547, Turnhoutseweg 30, B–2340 Beerse (BE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: FARNESYL PROTEIN TRANSFERASE INHIBITORS WITH *IN VIVO* RADIOSENSITIZING PROPERTIES

(57) Abstract

The present invention is concerned with the finding that farnesyl protein transferase inhibitors have radiosensitizing properties which makes them useful for preparing a pharmaceutical composition for administration before, during or after irradiation of a tumor for treating cancer *in vivo*.